Higher heart rate may predispose to obesity and diabetes mellitus: 20-year prospective study in a general population.

BACKGROUND Emerging evidence indicates an association between sympathetic activation and metabolic syndrome. However, sympathetic activation in metabolic syndrome may be a cause, consequence, or just epiphenomenon. To elucidate this issue, the predictive power of resting heart rate for the development of abnormal glucose and lipid metabolisms after 20 years was evaluated in a general population. METHODS A total of 637 participants (>20 years old) underwent a health examination in 1979 including measurements of blood chemistries. Resting heart rate (bpm) was measured by an electrocardiogram. In 1999, all of the study participants again underwent a health examination, including electrocardiogram and blood chemistries. Because four of them had atrial fibrillation, and 19 subjects were taking antihypertensive medication in 1979, they were excluded from analysis. Therefore, a complete dataset of 614 subjects was available. RESULTS As was reported in our previous article, in 1999 we found a linear and significant (P < 0.05) cross-sectional relationship between resting heart rate and a cluster of cardiometabolic risk factors (blood pressure (BP), free fatty acid (FFA), plasma glucose, and homeostasis model assessment (HOMA) index). Baseline higher heart rate (heart rate >or=80 bpm in 1979) predicted the development of obesity, diabetes mellitus (DM), and insulin resistance in 1999 after adjustments for age, sex, and other confounders. CONCLUSION This is one of the first prospective reports demonstrating that higher heart rate may predispose to the development of obesity and DM, suggesting that the sympathetic nerve system may play a role in the development of obesity and DM.

[1]  T. Ogihara,et al.  Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. , 2003, Hypertension research : official journal of the Japanese Society of Hypertension.

[2]  R. DeFronzo,et al.  Epinephrine-induced insulin resistance in man. , 1980, The Journal of clinical investigation.

[3]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[4]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[5]  E Casiglia,et al.  High heart rate: a risk factor for cardiovascular death in elderly men. , 1999, Archives of internal medicine.

[6]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[7]  K. Kario,et al.  Comparison of the Effects of Cilnidipine and Amlodipine on Ambulatory Blood Pressure , 2005, Hypertension Research.

[8]  T. Ogihara,et al.  Serum Uric Acid and Plasma Norepinephrine Concentrations Predict Subsequent Weight Gain and Blood Pressure Elevation , 2003, Hypertension.

[9]  藤浦 芳久 Heart rate and mortality in a Japanese general population : an 18-year follow-up study , 2001 .

[10]  K. Shimamoto,et al.  Clinical diagnosis of metabolic syndrome 1. Metabolic syndrome and insulin resistance. , 2007, Internal medicine.

[11]  G. Mancia,et al.  Metabolic Syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) Study: Daily Life Blood Pressure, Cardiac Damage, and Prognosis , 2007, Hypertension.

[12]  E Casiglia,et al.  Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with mixture analysis in three populations. , 1997, Hypertension.

[13]  P. Nestel,et al.  Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. , 2005, The Journal of clinical endocrinology and metabolism.

[14]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[15]  S A Stansfeld,et al.  Adrenocortical, Autonomic, and Inflammatory Causes of the Metabolic Syndrome: Nested Case-Control Study , 2002, Circulation.

[16]  S. Julius,et al.  Heart rate and the cardiovascular risk , 1997, Journal of hypertension.

[17]  R. Gillum,et al.  The epidemiology of resting heart rate in a national sample of men and women: associations with hypertension, coronary heart disease, blood pressure, and other cardiovascular risk factors. , 1988, American heart journal.

[18]  Paolo Palatini,et al.  Heart rate: a strong predictor of mortality in subjects with coronary artery disease. , 2005, European heart journal.

[19]  P Ducimetière,et al.  Prognostic significance of exercise blood pressure and heart rate in middle-aged men. , 1992, Hypertension.

[20]  G. Mancia,et al.  The sympathetic nervous system and the metabolic syndrome. , 2007, Journal of hypertension.

[21]  G. Sharp Two-way street. , 1971, AORN journal.

[22]  Elisabeth Lambert,et al.  Mechanisms of sympathetic activation in obesity-related hypertension. , 2006, Hypertension.

[23]  J. Shaw,et al.  The metabolic syndrome: a global public health problem and a new definition. , 2005, Journal of atherosclerosis and thrombosis.

[24]  S. Julius,et al.  Overweight and hypertension : a 2-way street? , 2000, Hypertension.

[25]  R S Paffenbarger,et al.  Heart rate and cardiovascular mortality: the Framingham Study. , 1987, American heart journal.

[26]  S. Julius,et al.  The interconnection between sympathetics, microcirculation, and insulin resistance in hypertension. , 1992, Blood pressure.

[27]  T. Laitinen,et al.  Weight loss and weight maintenance, ambulatory blood pressure and cardiac autonomic tone in obese persons with the metabolic syndrome , 2003, Journal of hypertension.

[28]  R. Lauer,et al.  Left Ventricular Hypertrophy in Children with Blood Pressures in the Upper Quintile of the Distribution: The Muscatine Study , 1981, Hypertension.

[29]  R. Brook,et al.  Attenuation of haemodynamic, metabolic and energy expenditure responses to isoproterenol in patients with hypertension , 2004, Journal of hypertension.

[30]  D. McGee,et al.  Biological and Social Correlates of Blood Pressure Among Japanese Men in Hawaii , 1982, Hypertension.

[31]  S. Julius,et al.  Sympathetics, insulin resistance and coronary risk in hypertension: the 'chicken-and-egg' question. , 1994, Journal of hypertension.

[32]  J. D. Etlinger,et al.  Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a beta 2-receptor agonist. , 1988, The American journal of physiology.

[33]  T. Ogihara,et al.  Questionnaire survey on the Japanese guidelines for treatment of hypertension in the elderly: 1999 revised version. , 2002, Hypertension research : official journal of the Japanese Society of Hypertension.

[34]  A. Mainous,et al.  Long-term prognostic value of resting heart rate in subjects with prehypertension. , 2006, American journal of hypertension.